SafeGuard Surgical
SafeGuard Surgical is a pioneering medical technology company dedicated to redefining surgery through innovative, biodegradable solutions. Their flagship platform, LeakGuard™, is an FDA breakthrough, U.S.-manufactured solution designed to prevent surgical leaks, reduce complications, and improve patient outcomes across multiple surgical applications. The company aims to save lives, cut costs, and reduce medical waste by providing scalable, environmentally friendly surgical innovations.
Industries
Nr. of Employees
small (1-50)
SafeGuard Surgical
Tampa, Florida, United States, North America
Patents
Products
Biodegradable implantable stent for anastomotic protection
An implantable biodegradable stent designed to protect intestinal anastomoses during healing, prevent postoperative leaks, reduce the need for colostomy and reversal surgery, and pass without device removal.
Biodegradable implantable stent for anastomotic protection
An implantable biodegradable stent designed to protect intestinal anastomoses during healing, prevent postoperative leaks, reduce the need for colostomy and reversal surgery, and pass without device removal.
Services
Company-provided contact channel for investor, clinical trial, and commercial partnerships; intake via web contact form.
Company-provided contact channel for investor, clinical trial, and commercial partnerships; intake via web contact form.
Expertise Areas
- Anastomotic leak prevention
- Biodegradable medical device development
- Preclinical in vivo device evaluation
- U.S. medical device manufacturing and scale-up
Key Technologies
- Biodegradable implantable stent
- Biocompatible biodegradable polymers for implants
- In vivo time-course imaging for preclinical studies
- Health-economic and reimbursement modeling
News & Updates
SafeGuard Surgical announced a major milestone with FDA granting 'Breakthrough' designation to its biodegradable stent, LeakGuard™, and securing funding from notable investors.
An article discussing the rising rates of colorectal cancer among people under 50, highlighting the importance of innovative solutions like LeakGuard™.
Research shows increasing colorectal cancer rates among young populations, emphasizing the need for advanced surgical interventions.
A report on the rise of colorectal cancer among young adults and ongoing scientific efforts to understand this trend.
SafeGuard Surgical announced a major milestone with FDA granting 'Breakthrough' designation to its biodegradable stent, LeakGuard™, and securing funding from notable investors.
An article discussing the rising rates of colorectal cancer among people under 50, highlighting the importance of innovative solutions like LeakGuard™.
Research shows increasing colorectal cancer rates among young populations, emphasizing the need for advanced surgical interventions.
A report on the rise of colorectal cancer among young adults and ongoing scientific efforts to understand this trend.